It has been observed that the inhibition or deficiency of PCSK9 can yield therapeutic benefits in cancer treatment, by not only curbing tumorigenesis but also enhancing anti-tumor immunity.440,441 Encouragingly, several therapeutic strategies designed to directly inhibit PCSK9 have already been rigorously explored in the context of hyperlipidemia management. The gene discussed is PCSK9; the disease is hyperlipidemia.